GLP1R and atrial fibrillation: Although cardiovascular benefit has been observed in obese patients without diabetes, meta-analyses of randomized controlled trials did not show significant differences regarding the incidence of arrhythmia, including AF, in patients treated with GLP-1 RA [74,75].